Found 100 Enz. Inhib. hit(s) with all data for entry = 6471 TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 0.400nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 1.10nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 1.20nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 1.30nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 1.70nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 1.70nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 1.70nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 2nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 2.10nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 2.20nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 2.40nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 2.5nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 2.80nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 3nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 3.20nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 3.30nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 3.30nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 3.5nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 3.70nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 3.80nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 3.90nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 3.90nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 4.30nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 4.30nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 4.40nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 4.40nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 4.40nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 4.40nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 4.40nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 4.70nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 4.70nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 4.70nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 5nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 5.10nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 5.20nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 5.20nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 5.5nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 5.70nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 5.70nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 5.80nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 5.90nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 6.10nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 6.20nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 6.30nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 6.60nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 6.80nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 6.90nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 7nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 7.5nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Rattus norvegicus (Rat))
Astellas Pharma
US Patent
Astellas Pharma
US Patent
Affinity DataIC50: 7.5nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
